Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MZT..bladder cancer detection kits..shares under a buck Johns
MZT news...Scimitar Equity Research Issues Review on Matritech, Inc.
Wednesday February 8, 8:30 am ET
BOSTON, Feb. 8 /PRNewswire-FirstCall/ -- Scimitar Equity Research, Inc. issues a review on Matritech, Inc. (Amex: MZT - News) entitled "A Prelude to a Standard of Care Designation." The analyst research review is available on Scimitar's website, www.scimitarequity.com.
ADVERTISEMENT
Scimitar Equity Research, Inc. provides sponsored equity research of the health sciences industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about (Amex: MZT - News) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.
Divide your existing shares by 80 and then multiply your base cost by 80...is that correct? TIA
Matritech Reporting Fourth Quarter and 2005 Financial Results on February 7, 2006
NEWTON, Mass.--(BUSINESS WIRE)--Jan. 24, 2006--Matritech, Inc. (Amex:MZT) announced today that it will hold a conference call on Tuesday, February 7, 2006 at 8:30 a.m. Eastern Time to discuss fourth quarter and 2005 financial results and provide a company update. The call will be webcast and can be accessed on the Matritech web site at www.matritech.com.
In addition to access on the Matritech website, the webcast will also be distributed over CCBN's Investor Distribution Network to both institutional and individual investors. The conference call may be accessed by dialing 866-362-4832 for domestic callers and 617-597-5364 for international callers. The participant passcode is 31221329.
About Matritech
Matritech is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22(R) Test Kit and NMP22(R) BladderChek(R) Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22(R) BladderChek(R) Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech's patent portfolio has grown to more than 15 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22(R) Test Kit and NMP22(R) BladderChek(R) Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company's goal is to utilize these protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com.
Lebed,in my opinion detracts big time here...why him for a class company like this and the watch dogs....if you catch my drift. Johnsbus
I did this a few years ago with K-mart (a Fleming Co.). I held over the weekend not knowing if they would go ch-11 or BK. Monday on the open it was make or break..literally. They went ch-11 and the PPS surged. Over the next 3 days i made tons. This is what i love. GLA,Johnsbus
Thats what i like about it. A nice slow ascent without drawing much attention. Up and up then... boooooom. It`s off to the races and were in the lead. Johnsbus
Thanks for the DD. Since i have only a few mil/sh i look it as a 50/50 deal. Maybe yes , maybe no. Whatever.Johnsbus
i bought a bunch last week..long term.
Maybe quiet because of the competition? Perhaps there is a deal in the works? They may have shut the lights out for the last time? Now i`m escared. ;} Time for the snow blower-later. Johnsbus
I traded over the phone after CNBC mentioned a stock i had been following. It really hurt when the meds wore off(it was trading around 17$ and heading north but the order was processed @23$ because it was at the mkt. OOOWWWWWW)
On meds caution...i lost a ton when on pain killers in the hosp. ...put in mkt. order(instead of limit)over the phone. Lesson learned. johns
making 130% on SYTE-long term, eom
AXNP,phone cards for transplanted people,servicemen/women, refugees,students and "the US govt"....AMAR,bird flu up since last week..... MZT, in office bladder cancer detection test(firefighters at high risk etc.)....SRGX,the gov`t can`t do it.....XDSL,nanobatteries this months Scientific American article....ITGJ, big time vol.
I have been on this for months and really stumped over no price appreciation.
Any north of Boston suppliers. Was it Shaws getting the products??? TIA-Johnsbus
XDSL.Bell Labs partner,nanobatteries this months Scientific American plus........New Online Video Features mPhase Technologies' Uncooled Magnetometer Prototype
Thursday January 12, 4:32 pm ET
News Segment Suggests Tiny Device May Transform Multiple Markets
LITTLE FALLS, N.J.--(BUSINESS WIRE)--Jan. 12, 2006--mPhase Technologies (OTCBB:XDSL - News) today is making available on its website a new video news segment about a metal detector under development that could be used in homeland security, military perimeter defense, and in avoiding oil spills by spotting hidden faults in pipelines or an oil tanker's hull.
ADVERTISEMENT
The video report, prepared by Maxworld News, a global provider of television news to TV networks and local broadcasters, is now viewable from the mPhase Technologies home page, www.mphasetech.com. The segment describes the wide-ranging potential applications for the prototype device that mPhase is developing in collaboration with Lucent Technologies Bell Labs.
Unlike commercially available ultra-sensitive metal detectors, the mPhase prototype, also called a magnetometer, requires no cooling. Magnetometers detect changes or disturbances in magnetic fields and derive information such as presence, size, location and orientation of objects, such as metal, that have magnetic properties. Theoretically 1000 times more magnetically sensitive than comparable solutions available on the market today, the prototype is based on research pioneered at Bell Labs.
About mPhase Technologies, Inc.
mPhase Technologies Inc. (OTCBB: XDSL - News) develops and commercializes next-generation telecommunications and nanotechnology solutions, delivering novel systems to the marketplace that advance functionality and reduce costs. The company, awarded the 2005 Frost & Sullivan Excellence in Technology Award and named to the NASA Nanotech Briefs "Nano 50", is bringing nanotechnology out of the laboratory and into the market with a planned innovative long life power cell. Additionally, the company is working on prototype ultra-sensitive magnetometers that promise up to a 1,000-fold increase in sensitivity as compared with available uncooled sensors. More information is available at the mPhase Web site at www.mPhaseTech.com.
FDA approved in office bladder cancer test kit..............Matritech's NMP22(R) BladderChek(R) Test Detects Bladder Cancers in Symptomatic Patients Missed by Traditional Laboratory Test
Thursday January 19, 11:40 am ET
Military Veterans with Blood in Their Urine Reported to Have Twice the Incidence of Bladder Cancer as Other Individuals
SAVANNAH, Ga.--(BUSINESS WIRE)--Jan. 19, 2006--Giora Katz, M.D., a urologist with the Lake City Veterans' Hospital in Lake City, Florida reported today that in a recent bladder cancer clinical trial including veterans hospitals, Matritech's (Amex: MZT - News) NMP22® BladderChek® Test detected three times more cases of bladder cancer in symptomatic patients than the traditional laboratory test, cytology. These results were from a new analysis of a large clinical trial published in the Journal of the American Medical Association (JAMA) in February, 2005. This week JAMA also reported that the point-of-care NMP22 BladderChek Test significantly increased the detection of recurrent bladder cancer, finding 99% of the malignancies when used with cystoscopy (a visual examination of the interior of the bladder).
ADVERTISEMENT
Dr. Katz, a co-author on both JAMA studies evaluated the effectiveness of the BladderChek Test for diagnosis of bladder cancer in patients with hematuria (blood in the urine). He presented his findings today at the 53rd Annual James C. Kimbrough Urological Seminar in Savannah, Georgia, sponsored by the Uniformed Services University of the Health Sciences and the Society for Government Service Urologists.
The data presented by Dr. Katz showed the NMP22 BladderChek Test, which identifies a protein in the urine for bladder cancer, detected four life threatening cancers missed by cystoscopy, three invasive tumors and one non-invasive, but aggressive malignancy. When the BladderChek Test was combined with the diagnostic standard, cystoscopy, it significantly increased overall bladder cancer detection. The new data confirm similar findings of the test's effectiveness in detecting recurrent bladder cancer published in the January 18, 2006 issue of JAMA.
The two participating veterans' hospitals represented 9% of the sites in the study, but accounted for 16% of the cancers. That was because, although the patients at all sites presented with the same symptoms, such as hematuria, or painful or frequent urination, the percentage of those diagnosed with bladder cancer at the veterans' hospitals was 11.1%, compared to 5.7% at the community and academic practices. In addition, most of the malignancies at VA hospitals were already in an early invasive stage, compared to the other sites where the most common stage was noninvasive.
Dr. Katz commented, "The VA is the largest provider of health care in the country, and it provides excellent medical care to those who have served this country. It is not a surprise that the bladder cancer rate is high here. The American Cancer Society statistics show that bladder cancer occurs most commonly in men over the age of 60, and they make up a large proportion of our patient population. Moreover, smoking and occupational or environmental exposure to chemicals substantially increase the risk of urological malignancy, and many of our patients have these risk factors. We need to educate our patients and use the best tools we have to diagnose them early. The NMP22® BladderChek® Test is noninvasive, provides a result while my patient is in the office, is proven to improve detection of cancer, and is half the cost of laboratory tests. Considering the limited resources for healthcare in the VA and everywhere else, using the BladderChek Test will help identify those who need more urgent evaluation within a shorter period of time than others."
About Bladder Cancer
Bladder cancer is the fifth most common malignancy in the United States. There are over 500,000 people in the U.S. who have had bladder cancer, making it more prevalent in the population than lung and bronchial cancers. The American Cancer Society estimates that over 63,000 new cases of bladder cancer were diagnosed in the United States in 2005 (over 47,000 men and 16,000 women), and over 13,000 people died of the disease (nearly 9,000 men and 4,000 women). Worldwide it accounts for 330,000 new cases and 100,000 deaths each year. It is also one of the most chronic cancers, recurring in almost 70% of patients. The most common symptom of bladder cancer is blood in the urine, a condition referred to as hematuria.
Bladder cancer is diagnosed primarily in men age 60 and older (it does occur at younger ages) and roughly twice as frequently in white men as in black men. Men are three times more likely to be diagnosed with bladder cancer than women, but a greater percentage of women are diagnosed at an invasive stage of the malignancy. Among U.S. males, the incidence of new bladder cancer cases is almost as large as the incidence of colon cancer.
The most common risk factor for bladder cancer is smoking. Smokers are more than twice as likely to develop bladder cancer as nonsmokers. In the United States, smoking is estimated to be associated with about 50% of bladder cancer deaths among men and 30% among women.
Occupational exposures to chemicals (aromatic amines) used in dry cleaning facilities and the production of dyes, paper, rope, apparel, rubber and petroleum products have been associated with increased risk for bladder cancer. Other industrial exposures implicated as risk factors for developing bladder cancer include combustion gases and soot from coal, chlorinated aliphatic hydrocarbons, and chlorination by-products in heated water.
If diagnosed in its early stages, bladder cancer has a five-year survival rate of 94%. If diagnosed at an advanced stage, however, the five-year survival rate can be less than 10%. It has been estimated that this year in the United States about 25% of bladder cancer patients will be diagnosed after their disease has become invasive or metastatic, significantly lowering the five year survival rate.
Among U.S. women, according to the most recent SEER data, the prevalence of bladder cancer (140,000) is similar to the number of women with cervical (184,000) and ovarian (159,000) cancers. The five year survival rate of women is less than the ten year survival rate of men. Diagnosis in women may be delayed because symptoms are misinterpreted or attributed to other causes. This delay is correlated with a disproportionately higher death rate among women. In 2005 women accounted for one in four new bladder cancer diagnoses, but one in three bladder cancer deaths.
About the Study
The study included 1,331 patients from 23 sites in 10 states and included private practice, academic centers and VA hospitals. All patients were being evaluated for bladder cancer due to symptoms or risk factors. Of the total study population, 1,220 patients (91.7%) presented with hematuria. The study was designed to evaluate the clinical utility of the NMP22® BladderChek® Test, a point-of-care proteomic test, in enhancing the detection of bladder cancer. The performance of the NMP22 BladderChek Test, which measures the NMP22 nuclear matrix protein in urine, was compared to voided urine cytology, which must be analyzed in a clinical laboratory, and as an aid to cystoscopy in diagnosing bladder cancer among patients with hematuria.
About the NMP22® BladderChek® Test
The NMP22® BladderChek® Test was developed and is commercialized by Matritech (Amex: MZT - News), a leading developer of protein-based diagnostic products for the early detection of cancer. The NMP22 BladderChek Test detects elevated levels of the NMP22 protein in a single urine sample. Most healthy individuals have very small amounts of the NMP22 protein in their urine, but bladder cancer patients commonly have elevated NMP22 protein levels, even at early stages of the disease. The NMP22 BladderChek Test, a painless and non-invasive assay, is the only in-office test approved by the FDA for the diagnosis of bladder cancer. The BladderChek Test, which is reimbursed by Medicare and other medical insurers, is more cost effective than cell-based laboratory cytology tests. It is approved for use in a physician's office with results available during the patient visit, allowing a rapid, accurate and cost-effective way to aid in the detection of bladder cancer. NMP22 Tests have been approved by the FDA four times for two formats and claims, most recently in April 2003 for point-of-care use for diagnosis.
In May, 2005 the NMP22 BladderChek Test was featured in a number of platform presentations at the 100th annual meeting of the American Urological Association (AUA); these included clinical trial results and a cost impact analysis that demonstrated the costs of detecting a case of bladder cancer using the BladderChek Test are similar or less than currently accepted cancer screening methods such as mammography, PSA, and colonoscopy. Additionally, the NMP22 BladderChek Test was part of the curriculum in an AUA sponsored CME course on bladder cancer based on information presented at the annual meeting.
About Matritech
Matritech (Amex: MZT - News) is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22® Test Kit and NMP22® BladderChek® Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22 BladderChek Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech's patent portfolio has grown to more than 15 other U.S. patents. In addition to the NMP22® protein marker utilized in the NMP22® Test Kit and NMP22® BladderChek® Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company's goal is to utilize these protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com.
AMAR..3 day rise
MZT,FDA approved in office Matritech's NMP22(R) BladderChek(R) Test Detects Bladder Cancers in Symptomatic Patients Missed by Traditional Laboratory Test
Thursday January 19, 11:40 am ET
Military Veterans with Blood in Their Urine Reported to Have Twice the Incidence of Bladder Cancer as Other Individuals
SAVANNAH, Ga.--(BUSINESS WIRE)--Jan. 19, 2006--Giora Katz, M.D., a urologist with the Lake City Veterans' Hospital in Lake City, Florida reported today that in a recent bladder cancer clinical trial including veterans hospitals, Matritech's (Amex: MZT - News) NMP22® BladderChek® Test detected three times more cases of bladder cancer in symptomatic patients than the traditional laboratory test, cytology. These results were from a new analysis of a large clinical trial published in the Journal of the American Medical Association (JAMA) in February, 2005. This week JAMA also reported that the point-of-care NMP22 BladderChek Test significantly increased the detection of recurrent bladder cancer, finding 99% of the malignancies when used with cystoscopy (a visual examination of the interior of the bladder).
Dr. Katz, a co-author on both JAMA studies evaluated the effectiveness of the BladderChek Test for diagnosis of bladder cancer in patients with hematuria (blood in the urine). He presented his findings today at the 53rd Annual James C. Kimbrough Urological Seminar in Savannah, Georgia, sponsored by the Uniformed Services University of the Health Sciences and the Society for Government Service Urologists.
The data presented by Dr. Katz showed the NMP22 BladderChek Test, which identifies a protein in the urine for bladder cancer, detected four life threatening cancers missed by cystoscopy, three invasive tumors and one non-invasive, but aggressive malignancy. When the BladderChek Test was combined with the diagnostic standard, cystoscopy, it significantly increased overall bladder cancer detection. The new data confirm similar findings of the test's effectiveness in detecting recurrent bladder cancer published in the January 18, 2006 issue of JAMA.
The two participating veterans' hospitals represented 9% of the sites in the study, but accounted for 16% of the cancers. That was because, although the patients at all sites presented with the same symptoms, such as hematuria, or painful or frequent urination, the percentage of those diagnosed with bladder cancer at the veterans' hospitals was 11.1%, compared to 5.7% at the community and academic practices. In addition, most of the malignancies at VA hospitals were already in an early invasive stage, compared to the other sites where the most common stage was noninvasive.
Dr. Katz commented, "The VA is the largest provider of health care in the country, and it provides excellent medical care to those who have served this country. It is not a surprise that the bladder cancer rate is high here. The American Cancer Society statistics show that bladder cancer occurs most commonly in men over the age of 60, and they make up a large proportion of our patient population. Moreover, smoking and occupational or environmental exposure to chemicals substantially increase the risk of urological malignancy, and many of our patients have these risk factors. We need to educate our patients and use the best tools we have to diagnose them early. The NMP22® BladderChek® Test is noninvasive, provides a result while my patient is in the office, is proven to improve detection of cancer, and is half the cost of laboratory tests. Considering the limited resources for healthcare in the VA and everywhere else, using the BladderChek Test will help identify those who need more urgent evaluation within a shorter period of time than others."
About Bladder Cancer
Bladder cancer is the fifth most common malignancy in the United States. There are over 500,000 people in the U.S. who have had bladder cancer, making it more prevalent in the population than lung and bronchial cancers. The American Cancer Society estimates that over 63,000 new cases of bladder cancer were diagnosed in the United States in 2005 (over 47,000 men and 16,000 women), and over 13,000 people died of the disease (nearly 9,000 men and 4,000 women). Worldwide it accounts for 330,000 new cases and 100,000 deaths each year. It is also one of the most chronic cancers, recurring in almost 70% of patients. The most common symptom of bladder cancer is blood in the urine, a condition referred to as hematuria.
Bladder cancer is diagnosed primarily in men age 60 and older (it does occur at younger ages) and roughly twice as frequently in white men as in black men. Men are three times more likely to be diagnosed with bladder cancer than women, but a greater percentage of women are diagnosed at an invasive stage of the malignancy. Among U.S. males, the incidence of new bladder cancer cases is almost as large as the incidence of colon cancer.
The most common risk factor for bladder cancer is smoking. Smokers are more than twice as likely to develop bladder cancer as nonsmokers. In the United States, smoking is estimated to be associated with about 50% of bladder cancer deaths among men and 30% among women.
Occupational exposures to chemicals (aromatic amines) used in dry cleaning facilities and the production of dyes, paper, rope, apparel, rubber and petroleum products have been associated with increased risk for bladder cancer. Other industrial exposures implicated as risk factors for developing bladder cancer include combustion gases and soot from coal, chlorinated aliphatic hydrocarbons, and chlorination by-products in heated water.
If diagnosed in its early stages, bladder cancer has a five-year survival rate of 94%. If diagnosed at an advanced stage, however, the five-year survival rate can be less than 10%. It has been estimated that this year in the United States about 25% of bladder cancer patients will be diagnosed after their disease has become invasive or metastatic, significantly lowering the five year survival rate.
Among U.S. women, according to the most recent SEER data, the prevalence of bladder cancer (140,000) is similar to the number of women with cervical (184,000) and ovarian (159,000) cancers. The five year survival rate of women is less than the ten year survival rate of men. Diagnosis in women may be delayed because symptoms are misinterpreted or attributed to other causes. This delay is correlated with a disproportionately higher death rate among women. In 2005 women accounted for one in four new bladder cancer diagnoses, but one in three bladder cancer deaths.
About the Study
The study included 1,331 patients from 23 sites in 10 states and included private practice, academic centers and VA hospitals. All patients were being evaluated for bladder cancer due to symptoms or risk factors. Of the total study population, 1,220 patients (91.7%) presented with hematuria. The study was designed to evaluate the clinical utility of the NMP22® BladderChek® Test, a point-of-care proteomic test, in enhancing the detection of bladder cancer. The performance of the NMP22 BladderChek Test, which measures the NMP22 nuclear matrix protein in urine, was compared to voided urine cytology, which must be analyzed in a clinical laboratory, and as an aid to cystoscopy in diagnosing bladder cancer among patients with hematuria.
About the NMP22® BladderChek® Test
The NMP22® BladderChek® Test was developed and is commercialized by Matritech (Amex: MZT - News), a leading developer of protein-based diagnostic products for the early detection of cancer. The NMP22 BladderChek Test detects elevated levels of the NMP22 protein in a single urine sample. Most healthy individuals have very small amounts of the NMP22 protein in their urine, but bladder cancer patients commonly have elevated NMP22 protein levels, even at early stages of the disease. The NMP22 BladderChek Test, a painless and non-invasive assay, is the only in-office test approved by the FDA for the diagnosis of bladder cancer. The BladderChek Test, which is reimbursed by Medicare and other medical insurers, is more cost effective than cell-based laboratory cytology tests. It is approved for use in a physician's office with results available during the patient visit, allowing a rapid, accurate and cost-effective way to aid in the detection of bladder cancer. NMP22 Tests have been approved by the FDA four times for two formats and claims, most recently in April 2003 for point-of-care use for diagnosis.
In May, 2005 the NMP22 BladderChek Test was featured in a number of platform presentations at the 100th annual meeting of the American Urological Association (AUA); these included clinical trial results and a cost impact analysis that demonstrated the costs of detecting a case of bladder cancer using the BladderChek Test are similar or less than currently accepted cancer screening methods such as mammography, PSA, and colonoscopy. Additionally, the NMP22 BladderChek Test was part of the curriculum in an AUA sponsored CME course on bladder cancer based on information presented at the annual meeting.
About Matritech
Matritech (Amex: MZT - News) is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22® Test Kit and NMP22® BladderChek® Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22 BladderChek Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech's patent portfolio has grown to more than 15 other U.S. patents. In addition to the NMP22® protein marker utilized in the NMP22® Test Kit and NMP22® BladderChek® Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company's goal is to utilize these protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com
bladder cancer test.............
Last week someone posted that RB was history by this coming week. I tried to logon around noon but no luck. Here for good-Johnsbus
SYTE is growing deep roots and establishing itself quarter after quarter with good returns. Awhile back they repurchased some 25 million shares but this a core holding(DD every so often) so memory may be off a little. GLA,Johnsbus...p.s. DD with eggroll??? sounds right though
Yes you are correct about that e-mail. I was on the verge of moving over here for good anyway since i was already a member. The RB site appears shut down. Investors hub is very civil compared to "Dodge City". Good luck over here. Johnsbus
It`s been eight months since the last post and Johnsbus moves from RB right into an empty neighborhood. Where are my peep from the old hood? I`m long because every time i sell good things happen. later.Johns
Wow , you guys are nice to each other..this is great. I`m use to RB and getting stomped on all over the boards. I`m almost all moved in now. I rode the RS storm with my original holdings....I don`t scare easy. Somewhat tired from packing,later. Johnsbus
Thanks Early One, Actually i bought AMAR @ 1.10 in a portfolio for my son years ago. I liked it then and i guess good things are starting to happen. Thanks,Johnsbus
i have held AMAR for some years..... and expect recent rumblings will show financial rewards. In fact it`s been so long i need some refresher DD. Johnsbus
for some reason i can not access ADVK on that "other board". i know its there as two other posters said so. the week before i had the same problem with another symbol and i was given a link. I DON`T GET IT, so much new p.r. and the train is reversing right thru the station. i have been following this sector(music-DRM etc) for maybe 6-8 yrs and 5 companies later all i can say is "why no lift off?" long(2 accts) johnsbus